Net Cash Provided by (Used in) Financing Activities in USD of Lineage Cell Therapeutics, Inc. from 2010 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Lineage Cell Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2010 to Q1 2025.
  • Lineage Cell Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2025 was $5.04M, a 64% decline year-over-year.
  • Lineage Cell Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $35.9M, a 458% increase from 2023.
  • Lineage Cell Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $6.42M, a 294% increase from 2022.
  • Lineage Cell Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $1.63M, a 95.6% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)

Lineage Cell Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $5.04M -$8.98M -64% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-13
Q1 2024 $14M +$14M Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-13
Q1 2023 $1K* -$512K Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q1 2022 $513K -$20.5M -97.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q1 2021 $21M +$31M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q1 2020 -$10M -$10.6M -1750% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q1 2019 $606K -$27K -4.27% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q1 2018 $633K -$18.5M -96.7% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q1 2017 $19.1M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
Q1 2014 $12.1M -$985K -7.51% Jan 1, 2014 Mar 31, 2014 10-Q 2014-05-12
Q1 2013 $13.1M +$13.1M Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-12
Q1 2012 $0 -$690K -100% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-10
Q1 2011 $690K Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-10

Lineage Cell Therapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $35.9M +$29.4M +458% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-10
2023 $6.42M +$4.79M +294% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-10
2022 $1.63M -$35.3M -95.6% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-07
2021 $36.9M +$7.07M +23.7% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-09
2020 $29.9M +$29.2M +4740% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-10
2019 $617K -$5.16M -89.3% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-11
2018 $5.77M -$49.6M -89.6% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-12
2017 $55.4M +$22.6M +69% Jan 1, 2017 Dec 31, 2017 10-K 2019-03-14
2016 $32.8M -$32M -49.4% Jan 1, 2016 Dec 31, 2016 10-K 2018-03-15
2015 $64.8M Jan 1, 2015 Dec 31, 2015 10-K 2018-03-15
2013 $34.3M +$32.4M +1691% Jan 1, 2013 Dec 31, 2013 10-K 2014-03-17
2012 $1.91M -$1.95M -50.5% Jan 1, 2012 Dec 31, 2012 10-K 2014-03-17
2011 $3.86M -$21.9M -85% Jan 1, 2011 Dec 31, 2011 10-K 2014-03-17
2010 $25.8M Jan 1, 2010 Dec 31, 2010 10-K 2013-03-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.